Display options
Share it on

Onco Targets Ther. 2014 Jun 12;7:985-94. doi: 10.2147/OTT.S62887. eCollection 2014.

xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies.

OncoTargets and therapy

Jordi Martinez-Serra, Antonio Gutierrez, Saúl Muñoz-Capó, María Navarro-Palou, Teresa Ros, Juan Carlos Amat, Bernardo Lopez, Toni F Marcus, Laura Fueyo, Angela G Suquia, Jordi Gines, Francisco Rubio, Rafael Ramos, Joan Besalduch

Affiliations

  1. Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Balearic Islands, Spain.
  2. Department of Clinical Analysis, University Hospital Son Espases, Palma de Mallorca, Balearic Islands, Spain.
  3. Department of Pharmacy, University Hospital Son Espases, Palma de Mallorca, Balearic Islands, Spain.
  4. Department of Pathology, University Hospital Son Espases, Palma de Mallorca, Balearic Islands, Spain.

PMID: 24959085 PMCID: PMC4061162 DOI: 10.2147/OTT.S62887

Abstract

The xCELLigence system is a new technological approach that allows the real-time cell analysis of adherent tumor cells. To date, xCELLigence has not been able to monitor the growth or cytotoxicity of nonadherent cells derived from hematological malignancies. The basis of its technology relies on the use of culture plates with gold microelectrodes located in their base. We have adapted the methodology described by others to xCELLigence, based on the pre-coating of the cell culture surface with specific substrates, some of which are known to facilitate cell adhesion in the extracellular matrix. Pre-coating of the culture plates with fibronectin, compared to laminin, collagen, or gelatin, significantly induced the adhesion of most of the leukemia/lymphoma cells assayed (Jurkat, L1236, KMH2, and K562). With a fibronectin substrate, nonadherent cells deposited in a monolayer configuration, and consequently, the cell growth and viability were robustly monitored. We further demonstrate the feasibility of xCELLigence for the real-time monitoring of the cytotoxic properties of several antineoplastic agents. In order to validate this technology, the data obtained through real-time cell analysis was compared with that obtained from using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. This provides an excellent label-free tool for the screening of drug efficacy in nonadherent cells and discriminates optimal time points for further molecular analysis of cellular events associated with treatments, reducing both time and costs.

Keywords: drug discovery; leukemia; lymphoma; real-time cell analysis

References

  1. Cancer Cell Int. 2012 Jul 18;12(1):34 - PubMed
  2. J Immunol. 1992 Jul 15;149(2):615-21 - PubMed
  3. Hematology. 2008 Aug;13(4):236-43 - PubMed
  4. Chemother Res Pract. 2012;2012:283181 - PubMed
  5. Nat Med. 2003 Sep;9(9):1158-65 - PubMed
  6. Nat Rev Drug Discov. 2012 Jun 01;11(6):479-97 - PubMed
  7. Eur J Immunol. 1997 Jun;27(6):1530-8 - PubMed
  8. Blood. 1994 Feb 15;83(4):1039-50 - PubMed
  9. Blood. 2000 Sep 1;96(5):1926-32 - PubMed
  10. Toxicol In Vitro. 2013 Aug;27(5):1589-95 - PubMed
  11. J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3 - PubMed
  12. Cell Adh Migr. 2013 May-Jun;7(3):275-82 - PubMed
  13. PLoS One. 2012;7(10):e46536 - PubMed
  14. PLoS One. 2012;7(5):e37601 - PubMed
  15. Immunology. 2005 Jan;114(1):53-62 - PubMed
  16. Clin Cancer Res. 2011 Aug 1;17(15):5060-70 - PubMed
  17. Leuk Lymphoma. 1995 Jun;18(1-2):1-16 - PubMed
  18. Xenobiotica. 2010 Oct;40(10):681-90 - PubMed
  19. Clin Cancer Res. 2008 May 1;14(9):2519-26 - PubMed
  20. Nat Rev Cancer. 2009 Sep;9(9):665-74 - PubMed

Publication Types